Aethlon Medical IncNASDAQ:AEMD
- LAST PRICE1.9000
- TODAY'S CHANGE (%)0.2000 (11.7647%)
- Bid / Lots1.8300/ 5
- Ask / Lots1.9700/ 2
- Open / Previous Close1.7600 / 1.7000
- Day Range
- 52 Week Range
- Volume43,558
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AEMD |
|---|---|---|
| 09:32 ET | 934 | 1.76 |
| 09:33 ET | 1604 | 1.64 |
| 09:53 ET | 160 | 1.69 |
| 10:20 ET | 100 | 1.8 |
| 10:24 ET | 800 | 1.7436 |
| 10:47 ET | 1100 | 1.8 |
| 11:30 ET | 220 | 1.79 |
| 12:01 ET | 122 | 1.79 |
| 12:14 ET | 971 | 1.79 |
| 12:17 ET | 100 | 1.79 |
| 12:44 ET | 100 | 1.79 |
| 12:48 ET | 2164 | 1.7899 |
| 12:50 ET | 4385 | 1.8371 |
| 01:09 ET | 100 | 1.86 |
| 01:13 ET | 738 | 1.832 |
| 01:15 ET | 345 | 1.8745 |
| 01:18 ET | 2578 | 1.8799 |
| 01:20 ET | 510 | 1.88 |
| 01:54 ET | 482 | 1.86 |
| 02:09 ET | 1000 | 1.8899 |
| 02:12 ET | 9162 | 1.92 |
| 02:14 ET | 398 | 1.92 |
| 02:20 ET | 1200 | 1.97 |
| 02:23 ET | 3300 | 1.97 |
| 02:25 ET | 800 | 1.905 |
| 02:30 ET | 120 | 1.9174 |
| 02:43 ET | 387 | 1.891 |
| 02:45 ET | 865 | 1.92 |
| 02:57 ET | 100 | 1.9 |
| 03:12 ET | 358 | 1.9 |
| 03:14 ET | 100 | 1.9 |
| 03:17 ET | 200 | 1.9 |
| 03:30 ET | 200 | 1.9199 |
| 03:32 ET | 150 | 1.91 |
| 03:33 ET | 200 | 1.9 |
| 03:35 ET | 920 | 1.92 |
| 03:39 ET | 621 | 1.91 |
| 03:55 ET | 1000 | 1.905 |
| 04:00 ET | 200 | 1.9 |
Nov 14, 2023
Aethlon Medical Announces Fiscal Second Quarter Financial Results and Provides Corporate Update, from 4:15PM ET on Tuesday Nov 14, 2023 by Dow Jones
4:15PM ET on Tuesday Nov 14, 2023 by Dow Jones*DJ Aethlon Medical 2Q Loss/Shr $1.22 >AEMD, from 4:15PM ET on Tuesday Nov 14, 2023 by Dow Jones
4:15PM ET on Tuesday Nov 14, 2023 by Dow Jones
Nov 13, 2023
Aethlon Medical Announces Appointment of James B. Frakes, M.B.A. as Interim Chief Executive Officer and Guy Cipriani, M.B.A. as Chief Operating Officer, from 8:01AM ET on Monday Nov 13, 2023 by Dow Jones
8:01AM ET on Monday Nov 13, 2023 by Dow Jones*DJ Aethlon Medical Announces Appointment Of James B. Frakes, M.B.A. As Interim Chief Executive Officer And Guy Cipriani, M.B.A. As Chief Operating Officer >AEMD, from 8:01AM ET on Monday Nov 13, 2023 by Dow Jones
8:01AM ET on Monday Nov 13, 2023 by Dow Jones
Nov 6, 2023
Aethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 14, 2023, from 8:01AM ET on Monday Nov 06, 2023 by Dow Jones
8:01AM ET on Monday Nov 06, 2023 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aethlon Medical Inc | 4.2M | -0.4x | --- |
Helius Medical Technologies Inc | 4.5M | 0.0x | --- |
Motus GI Holdings Inc | 3.1M | -0.1x | --- |
Advanced Biomedical Technologies Inc | 4.8M | -6.3x | --- |
Catheter Precision Inc | 3.0M | 0.0x | --- |
Kelyniam Global Inc | 1.9M | -2.5x | --- |
Company Information
Aethlon Medical, Inc. (Aethlon) is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections suppression, seed the spread of metastasis and inhibit the benefit of cancer therapies. The Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression. Hemopurifier helps to bind and clear multiple different glycosylated viruses, such as human immunodeficiency virus (HIV), hepatitis C virus (HCV), Dengue, West Nile, multiple strains of influenza, Ebola, Chikungunya, smallpox, monkeypox, multiple herpes viruses, a MERS-CoV related pseudovirus, and others. Hemopurifier is used as a device for two independent indications: the treatment of individuals with advanced or metastatic cancer and the treatment of life threating viruses that are not approved therapies.
Contact Information
- Headquarters
- 11555 Sorrento Valley Road, Suite 203SAN DIEGO, CA, United States 92121
- Phone
- 858-459-7800
- Fax
- ---
Executives
- Independent Chairman of the Board
- Edward Broenniman
- Interim Chief Executive Officer, Chief Financial Officer, Senior Vice President - Finance, Company Secretary, Director
- James Frakes
- Chief Operating Officer, Senior Vice President
- Guy Cipriani
- Chief Scientific Officer
- Lee Arnold
- Chief Medical Officer
- Steven Larosa
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.2M |
|---|---|
Revenue (TTM) | $574.3K |
Shares Outstanding | 2.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.41 |
EPS | $-4.89 |
Book Value | $6.55 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | 7.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,074.21% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
